CNR1 and myeloid sarcoma: The compound B2, able to activate both CB1R and CB2R, and targeting both the excitotoxic injury and neuroinflammation, might indeed offer a useful approach to treat MS and neurodegenerative disorders in which the excitotoxic cascade and neuroinflammation are activated.